Cynomolgus EWI-F / PTGFRN Protein (His Tag)
PTGFRN
- 100ug (NPP1850) Please inquiry
| Catalog Number | P90276-C08H |
|---|---|
| Organism Species | Cynomolgus |
| Host | Human Cells |
| Synonyms | PTGFRN |
| Molecular Weight | The recombinant cynomolgus PTGFRN comprises 816 amino acids and has a calculated molecular mass of 91.5 KDa. The apparent molecular mass of it is approximately 96-106 KDa in SDS-PAGE under reducing conditions. |
| predicted N | Val 26 |
| SDS-PAGE |  |
| Purity | > 95 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the cynomolgus PTGFRN (H9ERH4) (Met1-Lys830) was expressed with a polyhistidine tag at the C-terminus. |
| Bio-activity | |
| Research Area | Immunology |Signal Transduction |Signaling Pathway |Lipid Signaling |Prostaglandins |
| Formulation | Lyophilized from sterile PBS, pH 7.4. 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | EWI-F, also known as PTGFRN, is inversely related to the loss of CD9. Its expression correlates with the metastatic status of hLT (n=55). EWI-F inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. EWI-F expression positively correlates with the metastatic status of hLT, and that the upregulation of EWI-F expression could be one of the mechanisms underlying the loss of CD9 in solid tumours. |
| Reference |